Company profile: Invivyd
1.1 - Company Overview
Company description
- Provider of antibody-based therapies to protect vulnerable people from serious viral infectious diseases. Offers PEMGARDA, authorized for emergency use as pre-exposure prophylaxis against COVID-19 in certain adults and adolescents; the INVYMAB platform combining viral surveillance, predictive modeling, and antibody engineering; a pipeline of COVID-19 and influenza monoclonal antibody candidates; and clinical trials, including the CANOPY Phase 3 trial.
Products and services
- COVID-19 Antibody Candidates: Investigational-stage antibody products targeting SARS-CoV-2 for prevention or treatment of COVID-19, with multiple candidates advancing through various development stages across the pipeline
- INVYMAB Platform: Predictive-modeling-driven platform integrating viral surveillance and antibody engineering to generate monoclonal antibody candidates targeting circulating viral threats
- PEMGARDA: EUA-authorized antibody therapy for pre-exposure prophylaxis against COVID-19 in certain adults and adolescents, authorized for emergency use to help prevent illness before exposure
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Invivyd
Medical Products Laboratories
HQ: United States
Website
- Description: Provider of contract manufacturing and packaging for human and veterinary pharmaceuticals, medical devices, and nutritional supplements, including wet wipes. Offers product development (reverse engineering, new formulations, in‑vitro studies), laboratory testing (HPLC, GC, FTIR, UV spectrophotometry, wet chemistry), and CGMP regulatory and quality assurance support (ANDA, ANADA, 510(k)).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medical Products Laboratories company profile →
3P Biopharmaceuticals
HQ: Spain
Website
- Description: Provider of biologics and cell therapy development and manufacturing services. Offers comprehensive CDMO support, including process and analytical development, preclinical and clinical supply, and commercial production. Produces proteins via mammalian (CHO, NS0, BHK-21, HEK293, Hybridoma) and microbial (E. coli, P. pastoris, S. cerevisiae, H. pylori, S. noursei) systems, and provides cell therapy technology transfer, process development, cell culture, and GMP certification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 3P Biopharmaceuticals company profile →
Cellca
HQ: Germany
Website
- Description: Provider of upstream technologies and services for mammalian protein manufacturing, including a proprietary CHO expression platform, rapid cell line development (DNA to research cell bank in ~14 weeks), cGMP cell banking, cell line and product characterization, and cGMP lot release testing aligned with ICH and USP guidelines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellca company profile →
TCG Supplies
HQ: United States
Website
- Description: Provider of clinical trial materials management and centralized randomization services for the pharmaceutical research industry worldwide, including preparation and packaging/labeling of trial materials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TCG Supplies company profile →
Frenova
HQ: United States
Website
- Description: Provider of contract clinical research and site management for renal and adjacent conditions. Services include renal consulting, project management, bioinformatics and analytics; a global network of research-ready sites with tech-enabled patient screening and enrollment; data analytics/licensing with a 25-year longitudinal nephrology database; a genomics research program and the F1RST UP network to speed trial start-up.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Frenova company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Invivyd
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Invivyd
2.2 - Growth funds investing in similar companies to Invivyd
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Invivyd
4.2 - Public trading comparable groups for Invivyd
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →